Ascendis Pharma Reports Positive Phase 2 Results for TransCon hGH in Turner Syndrome

summarizeSummary

Ascendis Pharma announced positive Week 52 topline results from its Phase 2 New InsiGHTS trial, demonstrating TransCon hGH's efficacy and safety profile in prepubertal children with Turner syndrome is similar to daily somatropin.

check_boxKey Events

• Positive Phase 2 Trial Results

  Ascendis Pharma reported positive Week 52 topline results from its Phase 2 New InsiGHTS trial for TransCon hGH in prepubertal children with Turner syndrome.

• Efficacy Comparable to Standard of Care

  TransCon hGH demonstrated annualized height velocity (AHV) similar to daily somatropin, with an LS mean AHV of 9.05 cm/year for TransCon hGH-treated children compared to 9.04 cm/year for daily somatropin.

• Favorable Safety and Tolerability Profile

  The trial showed a safety and tolerability profile for TransCon hGH similar to daily somatropin, with adverse events being mild to moderate and no discontinuations due to AEs.

• Potential for New Indication

  These positive results support the potential expansion of TransCon hGH, an already FDA-approved drug for growth hormone deficiency, into the Turner syndrome market.

auto_awesomeAnalysis

This filing reports positive Week 52 topline results from the Phase 2 New InsiGHTS trial for TransCon hGH (lonapegsomatropin) in prepubertal children with Turner syndrome. The data indicates that once-weekly TransCon hGH achieved annualized height velocity similar to daily somatropin, with a comparable safety and tolerability profile. This is a significant step towards expanding the market for an already FDA-approved drug, potentially offering a convenient once-weekly option for children with Turner syndrome. Investors should monitor the company's plans for further development and regulatory submission for this indication, as it could contribute to future revenue growth.